Australian biotech company Anteris Technologies has collaborated with v2vmedtech to develop a new heart valve repair device designed for minimally invasive treatment of mitral and tricuspid valve regurgitation.
Currently being developed through physician-led research from New York Presbyterian/Columbia University Hospital, NYC, the device is designed to address unmet needs within the mitral and tricuspid valve repair space.
In an ASX announcement, Anteris said the mitral and tricuspid repair market is expected to reach $4.1 billion in 2028, but noted that the space is significantly unpenetrated with few competitors.
Furthermore, patients do not receive treatment due to current limitations in tech innovations.
The company said this represents an opportunity to work with highly credible physicians to bring innovation to an established but growing market with the structural heart space by developing a device that can expand the treatable patient population to include those unsuitable for today’s treatment options.
“This strategic partnership allows us to tap into our core capabilities of innovation and existing network of physician advisors while broadening our portfolio and entering additional market segments where we can expect significant long-term growth,” said Watene Paterson, CEO of Anteris.
As part of the partnership, Anteris will provide engineering, clinical, regulatory, marketing, and executive management resources to support the project’s development.
Under the agreement, v2v will own all intellectual property rights to the developed technology and development data from the activities from the development contributions.
The latest technology complements Anteris’ portfolio by entering a market adjacent to the transcatheter aortic valve replacement market, where the Australian company remains focused on the development of DurAVR TAVR system.
